High Lipoprotein(a): What Your Lp(a) Test Means for Heart Disease Risk
Lipoprotein(a), abbreviated Lp(a), is a genetically influenced blood lipoprotein associated with atherosclerotic cardiovascular disease. A high Lp(a) level can help explain inherited heart disease risk even when standard cholesterol measurements appear reasonably controlled.
Should adults have an Lp(a) blood test?
The 2026 ACC/AHA dyslipidemia guideline recommends measuring Lp(a) at least once in all adults for atherosclerotic cardiovascular risk assessment. Because Lp(a) is strongly influenced by genetics, a single appropriately performed test is often sufficient for the initial assessment. A clinician may consider the context of specific laboratory methods and units.
What does a high Lp(a) result mean?
The 2026 guideline identifies an Lp(a) level of 125 nmol/L or 50 mg/dL or greater as a risk-enhancing factor. Values of 250 nmol/L or 100 mg/dL or greater are associated with higher estimated risk. These thresholds are reported in different units, and direct conversion between mg/dL and nmol/L is unreliable for an individual result. Interpretation also depends on age, family history, cardiovascular risk factors, and existing disease.
Does high Lp(a) mean that a heart attack is inevitable?
A high Lp(a) level increases estimated risk at a population level; it does not determine any individual outcome. Preventive care can address other factors such as LDL cholesterol, blood pressure, diabetes, smoking, activity, and prescribed therapy. Decisions should integrate the complete clinical picture.
Should relatives also be tested?
The 2026 guideline recommends cascade testing of first-degree family members when high Lp(a), familial hypercholesterolemia, or premature atherosclerotic cardiovascular disease is present. A clinician can help determine how to communicate the family history and the appropriate testing pathway.
What questions should I bring to a preventive cardiologist?
Ask how the result changes your estimated risk, whether LDL cholesterol lowering should be intensified, whether additional risk assessment would be useful, and what family screening may be appropriate. Include your full lipid panel, medications, and family history of premature cardiovascular events.
What treatments are available?
Management usually emphasizes evidence-based control of modifiable cardiovascular risks and LDL cholesterol. The benefit and indication of any specific lipid therapy depends on the individual. Emerging Lp(a)-targeting therapies are an active research area; ask your clinician about the current regulatory and evidence status of any proposed treatment.
Further reading from My Heart Spark P.C.
Evidence and clinical sources
Request a virtual cardiology appointment
For chest pain suggestive of an emergency, severe breathlessness, fainting with concerning symptoms, or signs of stroke, call 911 or seek immediate emergency evaluation. This educational article is general information and does not establish a clinical relationship.
Comments